Home /
Active Studies
Evaluation of the effectiveness of Abrysvo® vaccine in pregnant women to prevent RSV hospitalization in their infants.
This is a collaborative study designed by iTrials - Equipo Ciencia, the Hub for Innovation in Health Policy and Equity (HubIPSE) of UNSAM, which aims to estimate the real-world impact and effectiveness of the RSVpreF vaccine (Abrysvo®, Pfizer) applied to pregnant women in the second and third trimester.
This program, called BERNI, demonstrated a high effectiveness of the vaccine in preventing hospitalizations for severe RSV-associated Acute Respiratory Infections (ARIb) during the first six months of life. This real-world and, moreover, local evidence from the first season of the program confirms and supports the findings of the MATISSE Phase 3 clinical trial.
The results of this study can be found in The Lancet.
We are conducting a multicenter observational study whose main objective is to estimate the direct and indirect financial and economic costs of severe acute illness caused by RSV for the health system, households and society in three representative Latin American countries.
The study also seeks to compare the specific direct and indirect costs of RSV-associated ARI with those of non-RSV-associated ARI.
Nasal vaccine against respiratory syncytial virus in infants, children and adolescents
Team Science conducted the PEARL study, which seeks to evaluate the efficacy, immunogenicity and safety of a live and attenuated nasal vaccine against respiratory syncytial virus in infants, boys and girls aged 6 to 22 months.
